Chasing Pfizer and J&J, Bayer’s Nubeqa nabs fast FDA nod in prostate cancer

31st July 2019 Uncategorised 0

Pfizer and Astellas’ Xtandi and Johnson & Johnson’s Erleada may have big head starts in the prostate cancer market, but Bayer and partner Orion have a new entry—and they’re looking to carve out a share.

More: Chasing Pfizer and J&J, Bayer’s Nubeqa nabs fast FDA nod in prostate cancer
Source: fierce